Camidanlumab tesirine - ADC Therapeutics

Drug Profile

Camidanlumab tesirine - ADC Therapeutics

Alternative Names: ADCT-301; HuMax®-TAC-ADC

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ADC Therapeutics; Genmab
  • Developer ADC Therapeutics
  • Class Antineoplastics; Benzodiazepines; Immunoconjugates; Monoclonal antibodies; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 23 Oct 2017 ADC Therapeutics plans a combination trial for Solid tumours
  • 23 Oct 2017 ADC Therapeutics plans registrational trials for ADCT 301 in 2018
  • 16 Jun 2017 Interim adverse events and efficacy data from a phase I trial in Hodgkin's disease and Non-Hodgkin's lymphoma(Second-line therapy or greater) released by ADC Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top